Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
Immuneering (Nasdaq: IMRX) has entered into a clinical supply agreement with Eli Lilly to evaluate its lead product candidate atebimetinib in combination with Lilly's olomorasib in a planned Phase 2 trial. The study will focus on patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy.
This marks Immuneering's second major collaboration in 2025, following a February agreement with Regeneron to evaluate atebimetinib with Libtayo®. Preclinical studies of the atebimetinib-olomorasib combination have shown promising results, including enhanced tumor regression and delayed resistance. Immuneering will retain global development and commercialization rights to atebimetinib.
Immuneering (Nasdaq: IMRX) ha stipulato un accordo per la fornitura clinica con Eli Lilly per valutare il suo candidato principale atebimetinib in combinazione con olomorasib di Lilly in uno studio di Fase 2 pianificato. Lo studio sarà rivolto a pazienti con carcinoma polmonare non a piccole cellule (NSCLC) KRAS G12C mutato, localmente avanzato o metastatico che hanno mostrato progressione dopo terapie precedenti.
Questo rappresenta la seconda importante collaborazione di Immuneering nel 2025, dopo l’accordo di febbraio con Regeneron per valutare atebimetinib con Libtayo®. Studi preclinici sulla combinazione atebimetinib–olomorasib hanno evidenziato risultati promettenti, tra cui una maggiore regressione tumorale e un ritardo nell’insorgenza di resistenza. Immuneering manterrà i diritti globali di sviluppo e commercializzazione di atebimetinib.
Immuneering (Nasdaq: IMRX) ha firmado un acuerdo de suministro clínico con Eli Lilly para evaluar su candidato principal, atebimetinib, en combinación con olomorasib de Lilly en un ensayo planificado de Fase 2. El estudio se centrará en pacientes con cáncer de pulmón no microcítico (CPNM) KRAS G12C mutado, localmente avanzado o metastásico que han progresado tras tratamientos previos.
Esta es la segunda colaboración importante de Immuneering en 2025, tras el acuerdo de febrero con Regeneron para evaluar atebimetinib con Libtayo®. Estudios preclínicos de la combinación atebimetinib–olomorasib han mostrado resultados prometedores, incluyendo una mayor regresión tumoral y un retraso en la aparición de resistencia. Immuneering conservará los derechos globales de desarrollo y comercialización de atebimetinib.
Immuneering (Nasdaq: IMRX)는 Eli Lilly와 임상물자 공급계약을 체결하고 자사 주요 후보물질인 아테비메티닙(atebimetinib)을 Lilly의 올로모라십(olomorasib)과 병용해 계획된 2상 시험에서 평가할 예정입니다. 이 연구는 이전 치료 후 진행된 국소 진행성 또는 전이성 KRAS G12C 돌연변이 비소세포폐암(NSCLC) 환자를 대상으로 합니다.
이번 계약은 2025년 Immuneering의 두 번째 주요 협력으로, 2월 Regeneron과의 아테비메티닙과 Libtayo® 병용 평가 계약에 이은 것입니다. 아테비메티닙–올로모라십 병용의 전임상 연구에서는 종양 퇴축 촉진과 내성 지연 등 유망한 결과가 관찰되었습니다. Immuneering은 아테비메티닙에 대한 전 세계 개발 및 상업화 권리를 유지합니다.
Immuneering (Nasdaq: IMRX) a conclu un accord d'approvisionnement clinique avec Eli Lilly pour évaluer son candidat principal atebimetinib en association avec l'olomorasib de Lilly dans un essai de phase 2 prévu. L'étude ciblera des patients atteints de cancer du poumon non à petites cellules (CPNPC) KRAS G12C muté, localement avancé ou métastatique ayant progressé après un traitement antérieur.
Il s'agit de la deuxième grande collaboration d'Immuneering en 2025, après l'accord de février avec Regeneron pour évaluer atebimetinib avec Libtayo®. Des études précliniques sur la combinaison atebimetinib–olomorasib ont montré des résultats prometteurs, notamment une régression tumorale accrue et un retard dans l'apparition de la résistance. Immuneering conservera les droits mondiaux de développement et de commercialisation d'atebimetinib.
Immuneering (Nasdaq: IMRX) hat eine klinische Liefervereinbarung mit Eli Lilly geschlossen, um seinen führenden Wirkstoffkandidaten Atebimetinib in Kombination mit Lillys Olomorasib in einer geplanten Phase‑2‑Studie zu prüfen. Die Studie richtet sich an Patienten mit lokal fortgeschrittenem oder metastasiertem KRAS G12C‑mutiertem nicht‑kleinzelligem Lungenkarzinom (NSCLC), die unter vorherigen Therapien progredient sind.
Dies ist Immuneerings zweite bedeutende Zusammenarbeit im Jahr 2025, nach der im Februar geschlossenen Vereinbarung mit Regeneron zur Evaluierung von Atebimetinib mit Libtayo®. Präklinische Studien zur Kombination Atebimetinib–Olomorasib zeigten vielversprechende Ergebnisse, darunter verstärkte Tumorregression und verzögerte Resistenzentwicklung. Immuneering behält die globalen Entwicklungs‑ und Vermarktungsrechte an Atebimetinib.
- Preclinical studies showed enhanced tumor regression and delayed resistance with the combination therapy
- Second major collaboration secured in 2025, demonstrating growing industry interest
- Company maintains global development and commercialization rights to atebimetinib
- Potential to address NSCLC market with limited effective treatment options
- Phase 2 trial is still in planning stages, not yet initiated
- Success in preclinical studies does not guarantee clinical trial effectiveness
Insights
Immuneering's partnership with Lilly to test atebimetinib+olomorasib represents a strategic advancement in targeted NSCLC therapy via dual RAS-MAPK pathway inhibition.
Immuneering's new clinical supply agreement with Eli Lilly marks a significant development in the company's oncology pipeline strategy. The collaboration will evaluate atebimetinib (IMM-1-104), Immuneering's dual MEK inhibitor, in combination with Lilly's second-generation KRAS G12C inhibitor olomorasib in Phase 2 trials for advanced KRAS G12c-mutant non-small cell lung cancer patients who have progressed on prior therapy.
The scientific rationale here is compelling. This combination creates a vertical blockade of the RAS-MAPK pathway, potentially delivering more comprehensive pathway inhibition than either agent alone. Preclinical studies cited in the release showed the combination produced enhanced tumor regression, delayed resistance emergence, and prolonged survival compared to monotherapy approaches.
This represents Immuneering's second major collaboration this year, following their February agreement with Regeneron to test atebimetinib with the PD-1 inhibitor Libtayo. This dual-partnership approach suggests a strategic effort to position atebimetinib in multiple combination regimens, potentially expanding its utility across different treatment contexts.
For NSCLC patients with KRAS G12C mutations, who typically have limited effective treatment options after progression, this combination approach targeting different points in the same critical signaling pathway could potentially overcome resistance mechanisms that often develop with single-agent therapies.
Importantly, Immuneering maintains global development and commercialization rights to atebimetinib, preserving significant future revenue potential if these combinations prove successful in clinical trials.
- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer –
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports the evaluation of Immuneering’s lead product candidate, atebimetinib (IMM-1-104), a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase 2 clinical trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy. In February 2025, Immuneering announced a clinical trial agreement with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with the anti-PD-1 therapy Libtayo® (cemiplimab) in patients with advanced non-small cell lung cancer.
“This agreement with Lilly marks the second such collaboration we have announced this year as we seek to evaluate the potential of atebimetinib in combination with synergistic anti-cancer mechanisms. A pan-MAPK solution is of particular interest in challenging tumor types such as NSCLC,” said E.B. Brakewood Chief Business Officer of Immuneering.
“The combination of atebimetinib and olomorasib has the potential to provide a vertical blockade of the RAS-MAPK pathway, which is supported by preclinical studies of this combination in which enhanced tumor regression, delayed emergence of tumor resistance and prolonged survival relative to monotherapy was observed. This dual targeted approach has the potential to improve outcomes in a population with limited effective treatment options,” said Igor Matushansky, MD, PhD, Chief Medical Officer of Immuneering.
Immuneering will maintain global development and commercialization rights to atebimetinib.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: our plans to develop, manufacture and commercialize our product candidates; the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including in advanced non-small cell lung cancer; the treatment potential of our pipeline product candidates in other types of cancer; the plans and objectives of Company management for future operations, including with respect to the timing, planning and execution of enrollment, and additional atebimetinib combination trials.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding and ability to continue as a going concern; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the three months ended June 30, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Media Contact for Immuneering:
Gina Nugent
Gina.nugent.external@immuneering.com
Investor Contact for Immuneering:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
What is the purpose of Immuneering's clinical supply agreement with Eli Lilly?
What were the results of preclinical studies for IMRX's atebimetinib-olomorasib combination?
How many major collaborations has Immuneering announced in 2025?
Who will maintain the commercialization rights for atebimetinib?
What type of cancer patients will be included in IMRX's planned Phase 2 trial?
